Journal of Leukemia
Open Access

Short Note on Acute Lymphoblastic Leukemia Chemotherapy: Symptoms and Diagnosis

Mascarenhas John^{* *}Correspondence: Mascarenhas John, Department of Medical Biology, Tisch Cancer Institute, New York, United States of America, Email:

Author info »

Description

Acute Lymphoblastic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal white blood cells called lymphoblasts. These immature cells do not function properly and eventually crowd out healthy blood cells, leading to symptoms such as fatigue, weakness, infections, and bleeding. ALL is the most common type of cancer in children, accounting for approximately 25% of all childhood cancers. However, it can also affect adults, although it is less common. The exact cause of ALL is unknown, but certain factors such as exposure to radiation, genetic abnormalities, and certain viral infections may increase the risk of developing the disease[1].

Diagnosis of ALL involves a combination of physical examination, blood tests, and bone marrow biopsy. A Complete Blood Count (CBC) is usually the first test performed to check the levels of various blood cells. If abnormal cells are detected, a bone marrow biopsy is performed to confirm the diagnosis and determine the extent of the disease. Treatment of ALL usually involves a combination of chemotherapy, radiation therapy, and sometimes bone marrow transplantation. The goal of treatment is to kill the cancer cells and allow healthy blood cells to grow. The specific treatment plan depends on the age of the patient, the extent of the disease, and other factors[2].

Chemotherapy is the primary treatment for ALL. It involves the use of drugs to kill cancer cells. Chemotherapy is usually given in cycles, with periods of rest in between to allow the body to recover. Depending on the extent of the disease, chemotherapy may be given orally, intravenously, or directly into the spinal fluid. Radiation therapy may also be used in the treatment of ALL. It involves the use of high-energy radiation to kill cancer cells. Radiation therapy is usually given after chemotherapy to eliminate any remaining cancer cells[3].

In some cases, bone marrow transplantation may be necessary to treat ALL. This involves replacing the patient's diseased bone marrow with healthy bone marrow from a donor. Bone marrow transplantation is a complex procedure that carries a high risk of complications, but it can be life-saving for some patients. The prognosis for ALL depends on several factors, including the age of the patient, the extent of the disease, and the response to treatment. Children with ALL generally have a better prognosis than adults, with a cure rate of approximately 90%. The cure rate for adults with ALL is lower, at around 40%-50%.

Despite advances in the treatment of ALL, the disease can still have significant long-term effects on survivors. Some survivors may experience physical and emotional challenges, such as chronic health conditions, infertility, and anxiety. Regular follow-up care is important to monitor for any late effects of treatment and provide support for survivors. Myeloid leukemia can be classified into several subtypes based on the type of white blood cell that is affected and the stage of the disease. Acute Myeloid Leukemia (AML) is a fast-growing form of the disease that requires prompt treatment, while Chronic Myeloid Leukemia (CML) is a slower-growing form that may be managed with ongoing monitoring and medication[4].

The exact causes of myeloid leukemia are not fully understood, but certain risk factors have been identified, including exposure to radiation or certain chemicals, certain genetic mutations, and certain medical conditions such as Down syndrome. Symptoms of myeloid leukemia may include fatigue, weakness, fever, frequent infections, unexplained weight loss, and swollen lymph nodes. Diagnosis typically involves a combination of blood tests, bone marrow biopsy, and imaging tests. Treatment for myeloid leukemia varies depending on the subtype and stage of the disease, as well as the patient's overall health. Options may include chemotherapy, radiation therapy, stem cell transplantation, targeted therapy, and supportive care to manage symptoms and side effects[5].

Overall, myeloid leukemia is a serious and potentially lifethreatening condition that requires prompt diagnosis and treatment. With advances in medical technology and ongoing research, there is hope for improved outcomes and quality of life for patients with this disease. In conclusion, acute lymphoblastic leukemia is a serious disease that requires prompt diagnosis and treatment. Although the prognosis for ALL has improved in recent years, the disease can still have significant long-term effects on survivors. It is important for patients with ALL to receive regular follow-up care to monitor for any late effects of treatment and provide support for survivors. Myeloid leukemia is a type of cancer that affects the blood and bone marrow. It is characterized by the uncontrolled growth of abnormal white blood cells called myeloblasts, which are usually responsible for fighting infection in the body.

References

1. Matutes E, Brito-Babapulle V, Swansbury J, J Ellis, R Morilla, C Dearden, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269-3274.

   [Crossref], [Google Scholar], [PubMed]

2. Matutes E, Garcia Talavera J, O'Brien M, Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol. 1986;64(1):111-124.

   [Crossref], [Google Scholar], [PubMed]

3. Brito-Babapulle V, Catovsky D. Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet. 1991;55(1):1-9.

   [Crossref], [Google Scholar], [PubMed]

4. Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;103(2):110-116.

   [Crossref], [Google Scholar], [PubMed]

5. Sorour A, Brito-Babapulle V, Smedley D, Yuille M, Catovsky D. Unusual breakpoint distribution of 8p abnormalities in T-prolymphocytic leukemia: a study with YACS mapping to 8p11-p12. Cancer Genet. 2000;121(2):128-132.

   [Crossref], [Google Scholar], [PubMed]